Haikou VTI Biological Institute

Haikou VTI Biological Institute (VTI) is a Chinese biotechnology company focused on the research and development of therapeutic vaccines and diagnostic tools for infectious diseases. The company is notably advancing a therapeutic HIV vaccine, LFnp24B.C, which is currently in Phase 2 clinical trials and utilizes a recombinant core antigen to induce specific T-cell responses. VTI also developed the ASACIR.TB (A. TB) assay, an interferon-gamma release assay (IGRA) for latent tuberculosis detection, which employs a patented intracellular antigen delivery technology. Additionally, the institute leverages its Protein Capsular Matrix Vaccine (PCMV) platform to develop multivalent vaccines for indications such as typhoid and pneumococcal diseases. VTI operates a primate research facility in Hainan and maintains strategic partnerships with international entities like PDTi and Mir Bioscience.